探索硫皮化物作为 propionate 的替代品,用于诱导动物模型中的良性前列腺增生
Solomon Owumi1, Esther M Pius1, Hikmah A Abdulganiyu1
1Cancer Research and Molecular Biology Research Laboratories, Department of Biochemistry, University of Ibadan, Ibadan 200005, Oyo State, Nigeria.
Toxics
|February 26, 2026
概括
建议在动物中诱导良性前列腺激增症 (BPH),使用硫皮化物模型,为BPH研究提供了与 propionate (TP) 模型相比易于获得和临床相关的替代方案.
科学领域:
- 泌尿病学和雄性病学 泌尿和雄性病学
- 实验病理学实验病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 良性前列腺增生症 (BPH) 是老年男性常见的健康问题.
- propionate (TP) 是一种标准但受控的物质,用于诱导动物模型中的BPH.
- 对于TP的受控物质地位,需要探索替代BPH诱导模型.
研究的目的:
- 为了比较 propionate (TP) 和硫化物在试验动物中诱导良性前列腺增生 (BPH) 的模型.
- 评估BPH诱导模型的可访问性,机制和临床相关性.
- 评估硫化物模型的毒理学概况.
主要方法:
- 在PubMed/MEDLINE,Embase和Web of Science中进行全面的文献搜索.
- 纳入标准侧重于使用或硫皮化物模型诱导BPH的研究.
- 专题数据提取和评估研究设计,严谨性和可信性.
主要成果:
- TP模型涉及接受注射的割的动物,导致DHT介导的上皮质增生.
- 硫皮化物模型是非侵入性的,使用完整的动物,并诱导高血性中介性BPH,影响树皮和上皮的增殖.
- 硫化物模型密切模仿人类BPH病原体,并提供与TP模型相比更好的可访问性.
结论:
- 硫化物模型是BPH诱导和研究的可行和推的替代方案,因为它的可访问性和更接近人类疾病的相似性.
- 虽然TP模式已经建立,但由于药物管制的地位,它存在后勤挑战,并要求动物割.
- 需要进一步研究硫皮化物对脏,肝脏和生殖系统等器官的毒理作用.
相关概念视频
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).